Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
We demonstrate a comparable outcome for cemiplimab as second-line treatment of BCC in our real-world patient cohort as reported in previous registration studies. Additionally, we found a trend for a more favorable outcome in first-line therapy, suggesting a rationale to further investigate cemiplimab as first-line treatment of advanced BCC.
Authors
- Patrick Terheyden (ORCID: https://orcid.org/0000-0002-5894-1677)
- Eggert Stockfleth (ORCID: https://orcid.org/0000-0002-1922-9062)
- Christina Scheel (ORCID: https://orcid.org/0000-0003-0566-4650)
- Bastian Schilling (ORCID: https://orcid.org/0000-0001-8859-4103)
- Ralf Gutzmer (ORCID: https://orcid.org/0000-0001-7921-2820)
- Christoffer Gebhardt (ORCID: https://orcid.org/0000-0001-7090-9584)
- Peter Möhr (ORCID: https://orcid.org/0000-0001-9639-6545)
- Yenny Angela (ORCID: https://orcid.org/0000-0002-6643-7286)
- Michael Weichenthal (ORCID: https://orcid.org/0000-0002-9060-4961)
- Claudia Pföhler (ORCID: https://orcid.org/0000-0003-0384-114X)
- Sebastian Haferkamp (ORCID: https://orcid.org/0000-0002-3894-8345)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Konstantin Drexler (ORCID: https://orcid.org/0009-0004-6601-6299)
- Viola K. DeTemple (ORCID: https://orcid.org/0000-0001-6246-8862)
- Friedegund Meier (ORCID: https://orcid.org/0000-0003-4340-9706)
- Elisabeth Livingstone (ORCID: https://orcid.org/0000-0001-8279-9239)
- Jan C. Simon (ORCID: https://orcid.org/0000-0002-5238-0063)
- Carola Berking (ORCID: https://orcid.org/0000-0003-0229-8931)
- Selma Ugurel (ORCID: https://orcid.org/0000-0002-9384-6704)
- Jessica Cecile Hassel (ORCID: https://orcid.org/0000-0001-7575-6230)
- Dirk Tomsitz (ORCID: https://orcid.org/0000-0003-0036-072X)
- Ulrike Leiter (ORCID: https://orcid.org/0000-0002-8019-1577)
- Martin Kaatz (ORCID: https://orcid.org/0000-0002-0650-2576)
- Imke von Wasielewski
- Franziska Jochims (ORCID: https://orcid.org/0000-0003-2279-2072)
- Lucie Heinzerling (ORCID: https://orcid.org/0000-0001-5718-3643)
- Valerie Glutsch
- Jens Ulrich
Institutions
- Goethe University Frankfurt (DE)
- Universität Hamburg (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- University Hospital Regensburg (DE)
- Medizinische Hochschule Hannover (DE)
- Düsseldorf University Hospital (DE)
- SRH Wald-Klinikum Gera (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- National Center for Tumor Diseases (DE)
- University Hospital Schleswig-Holstein (DE)
- Essen University Hospital (DE)
- University Hospital Leipzig (DE)
- University Cancer Center Hamburg (DE)
- Universitätsklinikum Würzburg (DE)
- University Hospital Frankfurt (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- St. Josef-Hospital (DE)
- Comprehensive Cancer Center Erlangen (DE)
- West German Heart and Vascular Center Essen (DE)
- University Hospital Carl Gustav Carus (DE)
- Johannes Wesling Klinikum Minden (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Duisburg-Essen (DE)
- Ludwig-Maximilians-Universität München (DE)
- Ruhr University Bochum (DE)
- Saarland University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1016/j.ejca.2025.115590
- Citations
- 1
- Primary Topic
- Hedgehog Signaling Pathway Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.81